Risk factors for ptld - Study guides, Class notes & Summaries

CPHON Exam 195 Questions with Verified Answers Classification of Methotrexate - CORRECT ANSWER antimetabolite (s-phase) Classification of mercaptopurine and thioguinine - CORRECT ANSWER antimetabolite(s-phase) Classification of fludarabine/nelarabine - CORRECT ANSWER anti-metabolite Classification of cytarabine/gemcitabine - CORRECT ANSWER antimetabolite Classification and sub-class of ironotecan/topotecan - CORRECT ANSWER Topoisomerase inhibitors (campotothecins) Classificatio...

BMTCN Review Chapter 7 - Survivorship IssuesSurvivors and Survivorship - correct answer An individual is considered a cancer survivor from the time of diagnosis through the balance of his/her life Survivorship is a distinct phase of the cancer experience Some patients do not embrace the term "cancer survivor" Some definitions acknowledge the impact of cancer survivorship on families, friends and caregivers HSCT Survivorship - correct answer Number is increasing -Improvements in ou...

BMTCN Review Chapter 7 - Survivorship IssuesSurvivors and Survivorship - correct answer An individual is considered a cancer survivor from the time of diagnosis through the balance of his/her life Survivorship is a distinct phase of the cancer experience Some patients do not embrace the term "cancer survivor" Some definitions acknowledge the impact of cancer survivorship on families, friends and caregivers HSCT Survivorship - correct answer Number is increasing -Improvements in ou...

What type of transplants commonly have PTLD as a secondary malignancy? - ANSWER-Allo HSCT with T-cell depleted graft Therapies associated with therapy-related acute leukemia and MDS - ANSWER-alkylating agents (eg. Cytoxan, cisplatin, melphalan, busulfan, ifos) , radiation, topoisomerase II inhibitors (eg. doxorubicin, etoposide, mitoxantrone) Genetic predispositions that increase risk of primary and secondary cancers - ANSWER-neurofibromatosis type 1, Fanconi anemia Risk factors for PTLD ...

What type of transplants commonly have PTLD as a secondary malignancy? - ANSWER-Allo HSCT with T-cell depleted graft Therapies associated with therapy-related acute leukemia and MDS - ANSWER-alkylating agents (eg. Cytoxan, cisplatin, melphalan, busulfan, ifos) , radiation, topoisomerase II inhibitors (eg. doxorubicin, etoposide, mitoxantrone) Genetic predispositions that increase risk of primary and secondary cancers - ANSWER-neurofibromatosis type 1, Fanconi anemia Risk factors for PTLD ...

What type of transplants commonly have PTLD as a secondary malignancy? - ️️Allo HSCT with T-cell depleted graft Therapies associated with therapy-related acute leukemia and MDS - ️️alkylating agents (eg. Cytoxan, cisplatin, melphalan, busulfan, ifos) , radiation, topoisomerase II inhibitors (eg. doxorubicin, etoposide, mitoxantrone) Genetic predispositions that increase risk of primary and secondary cancers - ️️neurofibromatosis type 1, Fanconi anemia Risk factors for PTLD -...

What type of transplants commonly have PTLD as a secondary malignancy? - ANSWER-Allo HSCT with T-cell depleted graft Therapies associated with therapy-related acute leukemia and MDS - ANSWER-alkylating agents (eg. Cytoxan, cisplatin, melphalan, busulfan, ifos) , radiation, topoisomerase II inhibitors (eg. doxorubicin, etoposide, mitoxantrone) Genetic predispositions that increase risk of primary and secondary cancers - ANSWER-neurofibromatosis type 1, Fanconi anemia Risk factors for PTLD ...

What type of transplants commonly have PTLD as a secondary malignancy? Allo HSCT with T-cell depleted graft Therapies associated with therapy-related acute leukemia and MDS alkylating agents (eg. Cytoxan, cisplatin, melphalan, busulfan, ifos) , radiation, topoisomerase II inhibitors (eg. doxorubicin, etoposide, mitoxantrone) Genetic predispositions that increase risk of primary and secondary cancers neurofibromatosis type 1, Fanconi anemia Risk factors for PTLD T-cell de...

BMTCNWhat type of transplants commonly have PTLD as a secondary malignancy? - correct answer Allo HSCT with T-cell depleted graft Therapies associated with therapy-related acute leukemia and MDS - correct answer alkylating agents (eg. Cytoxan, cisplatin, melphalan, busulfan, ifos) , radiation, topoisomerase II inhibitors (eg. doxorubicin, etoposide, mitoxantrone) Genetic predispositions that increase risk of primary and secondary cancers - correct answer neurofibromatosis type 1, Fanconi a...

BMTCNWhat type of transplants commonly have PTLD as a secondary malignancy? - correct answer Allo HSCT with T-cell depleted graft Therapies associated with therapy-related acute leukemia and MDS - correct answer alkylating agents (eg. Cytoxan, cisplatin, melphalan, busulfan, ifos) , radiation, topoisomerase II inhibitors (eg. doxorubicin, etoposide, mitoxantrone) Genetic predispositions that increase risk of primary and secondary cancers - correct answer neurofibromatosis type 1, Fanconi a...